Informational only. Not medical advice.INFORMATIONAL PLATFORM ONLY — NOT MEDICAL ADVICE, DIAGNOSIS, OR TREATMENT
Informational only. Not medical advice.INFORMATIONAL PLATFORM ONLY — NOT MEDICAL ADVICE, DIAGNOSIS, OR TREATMENT
Head-to-head comparison of Ipamorelin and CJC-1295 — mechanism, dosing, side effects, legal status, and pricing.
Ipamorelin is a selective growth hormone secretagogue that stimulates the pituitary gland to release growth hormone. It is considered one of the mildest GHRPs with fewer side effects than alternatives like GHRP-6.
CJC-1295 is a synthetic analog of growth hormone-releasing hormone (GHRH) that stimulates sustained growth hormone secretion. The no-DAC (Drug Affinity Complex) version provides pulsatile GH release that more closely mimics natural physiology.
Ipamorelin
CJC-1295
Category
Legal Status
Mechanism
Dose Range
Route
Frequency
Dosing Notes
Side Effects
Contraindications
Clinical studies have demonstrated its ability to increase GH release in a dose-dependent manner. It has been studied in post-surgical recovery and bone health contexts. It is frequently combined with CJC-1295 for synergistic GH elevation.
Clinical trials have shown CJC-1295 increases GH and IGF-1 levels by 200–1000% without significantly altering other pituitary hormones. It is commonly studied in combination with GHRPs like ipamorelin for synergistic effects.
Ipamorelin and CJC-1295 are both in the Performance category and may have overlapping mechanisms. Researchers should review both profiles carefully, understand the mechanisms of action, and monitor the relevant biomarkers when combining compounds in the same class. As always, consult a licensed healthcare provider before making any decisions about combining research compounds.
This platform provides informational tools only, not medical advice. This comparison is for educational purposes only. Consult a licensed provider.
Disclosed Labs